Tirzepatide
Also known as: Mounjaro, Zepbound
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The combined incretin signaling improves glycemic control and strongly suppresses appetite, which makes nutrition adherence, protein sufficiency, hydration, nausea, and resistance-training performance the core coaching concerns.
- Tirzepatide Once Weekly for the Treatment of Obesity.
The New England journal of medicine · 2022 · PMID 35658024
FDA-approved dual GIP/GLP-1 RA. Start 2.5 mg weekly, increase by 2.5 mg every 4 weeks as tolerated.
No cycle range recorded.
Consistent day of week.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • History of pancreatitis
- • Severe gastroparesis
Common side effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Constipation
- • Decreased appetite
- • Abdominal pain
Serious risks
- • Acute pancreatitis
- • Gallbladder disease
- • Kidney injury
- • Thyroid C-cell tumors (boxed warning)
Drug interactions
- • Delays gastric emptying — oral contraceptive efficacy may be reduced; use backup contraception at dose changes
- • Insulin/sulfonylureas (hypoglycemia risk)
Requires monitoring
- • HbA1c
- • Weight
- • Kidney function
Pregnancy / breastfeeding
Contraindicated — discontinue before planned pregnancy
Female
Oral contraceptive effectiveness may be reduced at dose changes — use backup contraception for 4 weeks after any dose increase.
- Dual receptor action does not mean dose-stack — never combine with other GLP-1 agonists
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.